approach to iem aa - pku
DESCRIPTION
Approach to IEM AA - PKU. Annette Feigenbaum Division of Clinical and Metabolic Genetics, HSC 2002. Enzymes. Protein catalysts that rapidly mediate the chemical reactions in the body - PowerPoint PPT PresentationTRANSCRIPT
![Page 1: Approach to IEM AA - PKU](https://reader036.vdocument.in/reader036/viewer/2022081519/56812bd8550346895d904780/html5/thumbnails/1.jpg)
Approach to IEMAA - PKU
Annette FeigenbaumDivision of Clinical and Metabolic Genetics, HSC
2002
![Page 2: Approach to IEM AA - PKU](https://reader036.vdocument.in/reader036/viewer/2022081519/56812bd8550346895d904780/html5/thumbnails/2.jpg)
Enzymes
• Protein catalysts that rapidly mediate the chemical reactions in the body
• The clinical phenotype of an IEM is caused by metabolic disturbances resulting from the deficiency of a catalytic or transport protein.
![Page 3: Approach to IEM AA - PKU](https://reader036.vdocument.in/reader036/viewer/2022081519/56812bd8550346895d904780/html5/thumbnails/3.jpg)
Functional proteins
• Catalytic enzymes
• Transport - Famililal hypercholesterolemia, Cystic Fibrosis
• Structural - DMDystrophy, Osteogenesis I
• Homeostasis - immune response, clotting
• Growth and Differentiation
• Communication - receptors, hormones, transducers
![Page 4: Approach to IEM AA - PKU](https://reader036.vdocument.in/reader036/viewer/2022081519/56812bd8550346895d904780/html5/thumbnails/4.jpg)
Enzymopathies
• Usually autosomal recessive
• Substrate accumulation and/or product deficiency
• Small or large molecules
• Multiple enzymes can be affected in cofactor deficiencies
![Page 5: Approach to IEM AA - PKU](https://reader036.vdocument.in/reader036/viewer/2022081519/56812bd8550346895d904780/html5/thumbnails/5.jpg)
Also
• Deficiencies affecting dimerization
• Deficiencies of Modifying enzymes
• Organelle biosynthesis defects e.g peroxisomal
![Page 6: Approach to IEM AA - PKU](https://reader036.vdocument.in/reader036/viewer/2022081519/56812bd8550346895d904780/html5/thumbnails/6.jpg)
![Page 7: Approach to IEM AA - PKU](https://reader036.vdocument.in/reader036/viewer/2022081519/56812bd8550346895d904780/html5/thumbnails/7.jpg)
Amino and organic acidopathies
• small diffusible molecules disease
• acute encephalopathy
• catastrophic newborn disease or late onset subtle dev delay
• Importance– treatable
– prenatal available
– difficult to diagnose early to avoid brain damage
– mimic common medical problems e.g. sepsis
![Page 8: Approach to IEM AA - PKU](https://reader036.vdocument.in/reader036/viewer/2022081519/56812bd8550346895d904780/html5/thumbnails/8.jpg)
ACUTE ENCEPHALOPATHY Neonatal or later onset
• Amino acids– MSUD-acute, chronic ataxia, intermittent
variants– NKHG-seizures, spastic, dev delay– Homocystinemia + MMA (cobalamin)
• Organic acids– MMA, PA, IVA - acute/chronic/mild/severe
• Hypoglycemia – Fatty Acid Oxidation Defects e.g. MCAD
• Mitochondrial-acute/chronic• Hyperammonemia - UCED, FAOD, OA, PC
![Page 9: Approach to IEM AA - PKU](https://reader036.vdocument.in/reader036/viewer/2022081519/56812bd8550346895d904780/html5/thumbnails/9.jpg)
PKU / Phenylketonuria 1934
• Commonest IEM AA metabolism Caucasians-British, N. Europe
• Phenylalanine hydroxylase deficiency liver
• Autosomal recessive• Phenylalanine+BH4 ---X--->tyrosine + BH4
-->Dopamine
-->Norepinephrine -->Epinephrine
![Page 10: Approach to IEM AA - PKU](https://reader036.vdocument.in/reader036/viewer/2022081519/56812bd8550346895d904780/html5/thumbnails/10.jpg)
The Enzyme Defect
Phenylalanine Tyrosine
Protein
PAH
DHPR
PhenylpyruvicAcid
BH4
BH4 - tetrahydrobiopterin (cofactor)
DHPR - dihydropteridine reductase (recycles BH4)
qBH2
•Ingested•Catabolism
![Page 11: Approach to IEM AA - PKU](https://reader036.vdocument.in/reader036/viewer/2022081519/56812bd8550346895d904780/html5/thumbnails/11.jpg)
![Page 12: Approach to IEM AA - PKU](https://reader036.vdocument.in/reader036/viewer/2022081519/56812bd8550346895d904780/html5/thumbnails/12.jpg)
PKU-2
• Elevated Phenylalanine levels often >1000/even 2000uM
• normal: – adult 58+-15 uM– teenage 60 +-13– child 63+-18– newborn <120 uM ( 2mg/dl)
![Page 13: Approach to IEM AA - PKU](https://reader036.vdocument.in/reader036/viewer/2022081519/56812bd8550346895d904780/html5/thumbnails/13.jpg)
Classical PKU-small molecule disease
• Untreated severe MR, IQ <40, sz
• High Phe Dev delay
• Low Tyrosine Executive Fx
• Neurotransmitter deficiency ? Seizures
![Page 14: Approach to IEM AA - PKU](https://reader036.vdocument.in/reader036/viewer/2022081519/56812bd8550346895d904780/html5/thumbnails/14.jpg)
Heterogeneity
• Clinical-clinically different phenotypes
caused by mutations at the same locus
• Genetic- same or similar phenotypes caused
by different genetic mechanisms
![Page 15: Approach to IEM AA - PKU](https://reader036.vdocument.in/reader036/viewer/2022081519/56812bd8550346895d904780/html5/thumbnails/15.jpg)
Heterogeneity• Genetic
- same or similar phenotypes caused by different genetic mechanisms– Allelic
- different mutant alleles at the same locus, each capable of producing the abnormal phenotype e.g PKU, Hurler Scheie
– Locus- mutations at more than one
locus /gene can produce similar phenotypes e.g Tay Sachs vs Sandhoff disease; San Filippo
Note: need specific diagnosis to allow accurate carrier and prenatal testing
![Page 16: Approach to IEM AA - PKU](https://reader036.vdocument.in/reader036/viewer/2022081519/56812bd8550346895d904780/html5/thumbnails/16.jpg)
Clinical - Genetic heterogeneity• Classical PKU
– “severe”
– <1% residual enzyme activity
– very high levels PHE-strict diet for life
• Type II/Atypical PKU– milder
– tolerate more liberal protein diet
• Type III/Mild/Benign persistent Hyperphe– 5% residual activity
– levels <600uM
– no diet needed
• Type IV/Malignant PKU 2%– BH4 cofactor defect
– need neurotransmitter replacement therapy
– outcome often not good
![Page 17: Approach to IEM AA - PKU](https://reader036.vdocument.in/reader036/viewer/2022081519/56812bd8550346895d904780/html5/thumbnails/17.jpg)
PKU MRI - abnormal white matter
Even in treated PKU there are neurological consequences-learning, executive function problems etc
![Page 18: Approach to IEM AA - PKU](https://reader036.vdocument.in/reader036/viewer/2022081519/56812bd8550346895d904780/html5/thumbnails/18.jpg)
Treatment PKU
• Protein restriction 1954 ( Bickel) Phe free formulas/lo pro foods FOR LIFE
• Maternal PKU syndrome 1957– in -utero teratogenic effect of hyperPHE– micocephaly, MR, birth defects incl cardiac,
Cpalate, dysmorphic
• Gene therapy• Drug therapy - PAL• Liver transplant
![Page 19: Approach to IEM AA - PKU](https://reader036.vdocument.in/reader036/viewer/2022081519/56812bd8550346895d904780/html5/thumbnails/19.jpg)
PKU-3
• Chromosome 12q24.1• Gene cloned 1983 90kB, 13 exons• >350 mutations described-some common• Little genotype- phenotype correlation -
– combined/compund heterozygosity– mutations in modifying genes– variability of therapies and outcome measures
used- IQ, MRI, neuropsych testing– environmental factors
![Page 20: Approach to IEM AA - PKU](https://reader036.vdocument.in/reader036/viewer/2022081519/56812bd8550346895d904780/html5/thumbnails/20.jpg)
Mutations
• transcription- promotor
• RNA splicing/cleavage
• Point mutation: nonsense, frameshift, missense- null
• Large mutations: frameshift deletion, insertions, duplications- all null
![Page 21: Approach to IEM AA - PKU](https://reader036.vdocument.in/reader036/viewer/2022081519/56812bd8550346895d904780/html5/thumbnails/21.jpg)
Mutations-2• Abnormal amount or function of RNA• Abnormal/absent protein
– loss/reduction of function• enzyme deficiency• defect active site• abnormal multimeric assembly• impaired cofactor bindng• abnormal targetting/interaction
• Rarely gain of function e.g Huntington disease• Abnormal regulatory domain - altered level of
expression
![Page 22: Approach to IEM AA - PKU](https://reader036.vdocument.in/reader036/viewer/2022081519/56812bd8550346895d904780/html5/thumbnails/22.jpg)
PAH mutations
• Most common mutations (North America)– R408W Classical PKU (18.7%)– IVS12G-A+1 Classical PKU (7.8%)– Y414C Mild hyperphe (5.4%)– 13 other mutations (1-5%)– 55 other mutations (<1%)
31.9%
![Page 23: Approach to IEM AA - PKU](https://reader036.vdocument.in/reader036/viewer/2022081519/56812bd8550346895d904780/html5/thumbnails/23.jpg)
![Page 24: Approach to IEM AA - PKU](https://reader036.vdocument.in/reader036/viewer/2022081519/56812bd8550346895d904780/html5/thumbnails/24.jpg)
Genotype/Phenotype correlation
• Classical PKU: no good genotype phenotype relationship in most patients
• Complete or near complete enzyme deficiency leads to classical PKU
• Atypical/benign forms: disease severity in most determined by the least severe of 2 PAH mutations
• 2 mutations with similar severity may confer a milder phenotype than either would do alone
![Page 25: Approach to IEM AA - PKU](https://reader036.vdocument.in/reader036/viewer/2022081519/56812bd8550346895d904780/html5/thumbnails/25.jpg)
Mutation ClassificationMutation Classification
![Page 26: Approach to IEM AA - PKU](https://reader036.vdocument.in/reader036/viewer/2022081519/56812bd8550346895d904780/html5/thumbnails/26.jpg)
Prenatal Diagnosis
• Available - direct mutation, linkage
• Possible outcomes ie. Classical, atypical PKU
• ?Desired• perceived risk• burden• acceptable outcome
![Page 27: Approach to IEM AA - PKU](https://reader036.vdocument.in/reader036/viewer/2022081519/56812bd8550346895d904780/html5/thumbnails/27.jpg)
Maternal PKU
Untreated Risks• 92% MR• 73% microcephaly• 40% growth retardation• 12% congenital anomalies
Recommendations• maternal levels 120-360 mol/L preconception
throughout pregnancy; diet must be closely monitored to avoid fetal damage from malnutrition
![Page 28: Approach to IEM AA - PKU](https://reader036.vdocument.in/reader036/viewer/2022081519/56812bd8550346895d904780/html5/thumbnails/28.jpg)
PKU Neonatal screening
– Guthrie 1961– Ontario Started 1965
– Blood spot (filter paper) samples using the Guthrie bacterial inhibition assay
– Normal plasma Phe<0.24 mM.
– Cost effective: 2.5-6.6 cost benefit ratio
– Prevention maternal PKU syndrome
Horst Bickel and Robert Guthrie
![Page 29: Approach to IEM AA - PKU](https://reader036.vdocument.in/reader036/viewer/2022081519/56812bd8550346895d904780/html5/thumbnails/29.jpg)
![Page 30: Approach to IEM AA - PKU](https://reader036.vdocument.in/reader036/viewer/2022081519/56812bd8550346895d904780/html5/thumbnails/30.jpg)
PKU- plasma TLC screen
![Page 31: Approach to IEM AA - PKU](https://reader036.vdocument.in/reader036/viewer/2022081519/56812bd8550346895d904780/html5/thumbnails/31.jpg)
Urine amino acid qualitative screenUrine amino acid qualitative screen
![Page 32: Approach to IEM AA - PKU](https://reader036.vdocument.in/reader036/viewer/2022081519/56812bd8550346895d904780/html5/thumbnails/32.jpg)
Maple Syrup Urine Disease-quantitative amino acids -High Performance Liquid Chromatography
Normal
![Page 33: Approach to IEM AA - PKU](https://reader036.vdocument.in/reader036/viewer/2022081519/56812bd8550346895d904780/html5/thumbnails/33.jpg)
![Page 34: Approach to IEM AA - PKU](https://reader036.vdocument.in/reader036/viewer/2022081519/56812bd8550346895d904780/html5/thumbnails/34.jpg)
Neonatal screening Ontario
– The newborn screening program is a voluntary program not mandated by legislation
– Ontario Public Health Laboratories Branch and Public Health Branch
– The incidence in Ontario • PKU and it’s variants 1/12,00 births • Severe (Classical) form PKU 1/21,000 births.
• Present status Ontario: – PKU : Phenylalanine hydroxylase deficiency– Congenital Hypothyroidism 1:4000
![Page 35: Approach to IEM AA - PKU](https://reader036.vdocument.in/reader036/viewer/2022081519/56812bd8550346895d904780/html5/thumbnails/35.jpg)
Newborn population screeningPrinciples: PKU• common 1:±12 000 LB NA
• medically significant
• effective treatment diet
• test sensitive few false negatives <1%,may miss Type III
• test specific false positives
• easy to do, rapid Bacterial inhibition,Guthrie bloodspot, semiquantitative fluorometric better
• confirmatory test available blood amino acid analysis
• cost effective vs. cost of MRavoidance of maternal PKUprenatal
• access and support to follow-up and treatment
• centralized, coordinated, controlled, monitored, egalitarian
![Page 36: Approach to IEM AA - PKU](https://reader036.vdocument.in/reader036/viewer/2022081519/56812bd8550346895d904780/html5/thumbnails/36.jpg)
Costs of newborn screening
• Organisation, Administration• Sample collection and transportation to central lab• Laboratory- equipment, reagents, salaries• Program - data collection, record keeping, epidemiology, quality
assurance, check system• Confirmatory tests 10:1 false positive for PKU• Interprogram considerations• Communication - documentation, public education, parent
education, training health care personnel, staff training• Research and development- new techniques, new tests, new
diseases
![Page 37: Approach to IEM AA - PKU](https://reader036.vdocument.in/reader036/viewer/2022081519/56812bd8550346895d904780/html5/thumbnails/37.jpg)
Expanded Neonatal Screening
• By tandem MS– Organic / amino acidopathies-MSUD,
homocystinuria, tyrosinemia– Fatty acid oxidation defects e.g. MCAD
• Other– Biotinidase deficiency– Galactosemia– Other: CF, DMD, sickle cell, other
Hemoglobinopathies • AAP recommends integrated program that incorporates
screening, diagnosis, management and support
![Page 38: Approach to IEM AA - PKU](https://reader036.vdocument.in/reader036/viewer/2022081519/56812bd8550346895d904780/html5/thumbnails/38.jpg)
Liquid injection
Q1m/z mass
Q3m/z mass
Q2N2 Collision Cell
IonizationIon Spray Detector
Tandem Mass Spectrometry
Q1 Q2 Q3
Janice Fletcher
![Page 39: Approach to IEM AA - PKU](https://reader036.vdocument.in/reader036/viewer/2022081519/56812bd8550346895d904780/html5/thumbnails/39.jpg)
Tandem Mass Spectroscopy MS/MS
profile approach
screening for a wider group of disorders-39
shorter analytical time and high throughput
increased analytical sensitivity and specificity
earlier and more accurate screening in the post natal period
Advantages:
![Page 40: Approach to IEM AA - PKU](https://reader036.vdocument.in/reader036/viewer/2022081519/56812bd8550346895d904780/html5/thumbnails/40.jpg)
Advantages of Tandem MS
profile approach
screening for a wider group of disorders
shorter analytical time and high throughput
increased analytical sensitivity and specificity
earlier and more accurate screening in the post natal period
![Page 41: Approach to IEM AA - PKU](https://reader036.vdocument.in/reader036/viewer/2022081519/56812bd8550346895d904780/html5/thumbnails/41.jpg)
![Page 42: Approach to IEM AA - PKU](https://reader036.vdocument.in/reader036/viewer/2022081519/56812bd8550346895d904780/html5/thumbnails/42.jpg)
![Page 43: Approach to IEM AA - PKU](https://reader036.vdocument.in/reader036/viewer/2022081519/56812bd8550346895d904780/html5/thumbnails/43.jpg)
Plans
• Petition MOH Ontario to support expanded newborn screening by tandem MS and added tests as already exists in NS, Saskatchewan
• Establish the Coordinated Genetic Screening centre at HSC– Service, resource, support, education
![Page 44: Approach to IEM AA - PKU](https://reader036.vdocument.in/reader036/viewer/2022081519/56812bd8550346895d904780/html5/thumbnails/44.jpg)
Screening Populations at risk
• Ethnic based carrier screening-ADULTS – Black: sickle cell anemia – Oriental, Mediterranean: Thalassemia– Caucasian: Cystic fibrosis– Ashkenazi Jewish: Tay Sachs, Canavan disease, Familial
Dysautonomia, others• Population screening for affected - CHILDREN
– Sickle cell– CF
• Medical, Ethical, Legal, Social, Government, Insurance implications
• Tri-council mandate
![Page 45: Approach to IEM AA - PKU](https://reader036.vdocument.in/reader036/viewer/2022081519/56812bd8550346895d904780/html5/thumbnails/45.jpg)
Questions - 1
• What to do with PKU - a “positive newborn screen”?– A) stop breast feeds– B) change formula– C) refer to a genetic centre– D) repeat the screen
![Page 46: Approach to IEM AA - PKU](https://reader036.vdocument.in/reader036/viewer/2022081519/56812bd8550346895d904780/html5/thumbnails/46.jpg)
What to do if initial screen positive?
• You will get a report from MOH with the level asking for repeat sample within 5 days (usually > 0.24)
• Repeat the sample – 10:1 will be normal
• If repeat still positive esp. if >0.36…….
Explain to family and…..
![Page 47: Approach to IEM AA - PKU](https://reader036.vdocument.in/reader036/viewer/2022081519/56812bd8550346895d904780/html5/thumbnails/47.jpg)
Questions - 2
• What to tell the family with a second positive PKU screen?– A) call and refer to local PKU centre– B) restrict protein immediately– C) the child will be mentally retarded or die– D) do not have more children
![Page 48: Approach to IEM AA - PKU](https://reader036.vdocument.in/reader036/viewer/2022081519/56812bd8550346895d904780/html5/thumbnails/48.jpg)
What not to do….
• Do not stop or restrict feeds
• Do not stop breastfeeds
• Do not change to soya milk
• Do not tell family the child will be retarded or die
![Page 49: Approach to IEM AA - PKU](https://reader036.vdocument.in/reader036/viewer/2022081519/56812bd8550346895d904780/html5/thumbnails/49.jpg)
Refer to the designated PKU centre for follow-up
HSC, CHEO, KGH, CHWO, McMaster
What to do….
![Page 50: Approach to IEM AA - PKU](https://reader036.vdocument.in/reader036/viewer/2022081519/56812bd8550346895d904780/html5/thumbnails/50.jpg)
PKU follow-up at designated centre
• Quantitative plasma amino acids on HPLC
• Rule out biopterin synthesis defect
• Counseling
• Dietary intervention if needed
• Follow-up and monitoring
![Page 51: Approach to IEM AA - PKU](https://reader036.vdocument.in/reader036/viewer/2022081519/56812bd8550346895d904780/html5/thumbnails/51.jpg)
Questions - 3
• What is screened for in newborn screening? True or false– A) PKU– B) Hypothyroidism– C) Galactosemia– D) Organic acidopathies– E) Urea cycle defects– F) Fatty acid oxidation defects